Literature DB >> 11834772

Diabetic nephropathy: how effective is treatment in clinical practice?

N Joss1, K R Paterson, C J Deighan, K Simpson, J M Boulton-Jones.   

Abstract

BACKGROUND: Diabetic nephropathy is the most common cause of end-stage renal failure in patients starting dialysis in the developed world. In clinical trials, interventions, particularly blood pressure control, have achieved major reductions in the rate of decline in renal function. AIM: To investigate whether results from clinical trials can be achieved in routine clinical practice.
DESIGN: Observational study of 170 consecutive patients referred to a combined diabetic-renal clinic over a 10 year period.
METHODS: We collected demographic and laboratory data from the electronic patient record.
RESULTS: Median serum creatinine at referral was 170 micromol/l and was >350 micromol/l in 26% of patients. Mean blood pressure (BP) was 159/85. The publication of guidelines by the Scottish Intercollegiate Guidelines Network in 1997, recommending more active intervention and earlier referral, had no impact on referral BP and creatinine. In the 125 patients with at least 1 year follow-up, significant improvements in BP, albuminuria, HbA(1c) and serum cholesterol were seen. In the 63 patients followed up for 3 years (median creatinine 120 micromol/l), the median rate of decline in renal function slowed from 0.52 ml/min/month (first year) to 0.27 ml/min/month (third year) (p=0.003), nearly doubling the time to end-stage renal failure. DISCUSSION: Patients referred early to a combined diabetic-renal clinic benefited by slowing in the rate of decline of renal function. A challenging but achievable standard for audit would be to reduce the rate of progression to <0.25 ml/min/month in 70% of patients with diabetic nephropathy presenting with a serum creatinine <150 micromol/l.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11834772     DOI: 10.1093/qjmed/95.1.41

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  13 in total

1.  Increased urinary angiotensinogen is precedent to increased urinary albumin in patients with type 1 diabetes.

Authors:  Toshie Saito; Maki Urushihara; Yumiko Kotani; Shoji Kagami; Hiroyuki Kobori
Journal:  Am J Med Sci       Date:  2009-12       Impact factor: 2.378

2.  Young Scholars Award Lecture: Intratubular angiotensinogen in hypertension and kidney diseases.

Authors:  Hiroyuki Kobori; Yuri Ozawa; Yuki Suzaki; Minolfa C Prieto-Carrasquero; Akira Nishiyama; Tatsuya Shoji; Eric P Cohen; L Gabriel Navar
Journal:  Am J Hypertens       Date:  2006-05       Impact factor: 2.689

3.  Angiotensinogen Expression Is Enhanced in the Progression of Glomerular Disease.

Authors:  Maki Urushihara; Hiroyuki Kobori
Journal:  Int J Clin Med       Date:  2011-09-01

Review 4.  Blood pressure control--effects on diabetic nephropathy progression: how low does blood pressure have to be?

Authors:  Christopher A Newton; Philip Raskin
Journal:  Curr Diab Rep       Date:  2002-12       Impact factor: 4.810

5.  Low-protein vegetarian diet with alpha-chetoanalogues prior to pre-emptive pancreas-kidney transplantation.

Authors:  Giorgina B Piccoli; Daria Motta; Guido Martina; Valentina Consiglio; Massimo Gai; Elisabetta Mezza; Emanuela Maddalena; Manuel Burdese; Loredana Colla; Fabio Tattoli; Patrizia Anania; Maura Rossetti; Giorgio Soragna; Giorgio Grassi; Franco Dani; Alberto Jeantet; Giuseppe P Segoloni
Journal:  Rev Diabet Stud       Date:  2004-08-10

6.  Diabetic nephropathy: Treatment with phosphodiesterase type 5 inhibitors.

Authors:  Cecil Stanley Thompson
Journal:  World J Diabetes       Date:  2013-08-15

Review 7.  Augmented intrarenal and urinary angiotensinogen in hypertension and chronic kidney disease.

Authors:  Hiroyuki Kobori; Maki Urushihara
Journal:  Pflugers Arch       Date:  2012-08-24       Impact factor: 3.657

8.  Sequential activation of the reactive oxygen species/angiotensinogen/renin-angiotensin system axis in renal injury of type 2 diabetic rats.

Authors:  Kayoko Miyata; Naro Ohashi; Yuki Suzaki; Akemi Katsurada; Hiroyuki Kobori
Journal:  Clin Exp Pharmacol Physiol       Date:  2008-04-21       Impact factor: 2.557

Review 9.  Cardinal role of the intrarenal renin-angiotensin system in the pathogenesis of diabetic nephropathy.

Authors:  Hiroyuki Kobori; Masumi Kamiyama; Lisa M Harrison-Bernard; L Gabriel Navar
Journal:  J Investig Med       Date:  2013-02       Impact factor: 2.895

10.  Intrarenal oxidative stress and augmented angiotensinogen are precedent to renal injury in Zucker diabetic fatty rats.

Authors:  Yuki Suzaki; Yuri Ozawa; Hiroyuki Kobori
Journal:  Int J Biol Sci       Date:  2006-11-01       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.